Articles

The Relationship between Immunological Markers, Disease Free Survival and Overall Survival in Acute Myeloid Leukemia in North-West of Iran

Abstract

Introduction: Acute myeloid leukemia (AML) is a clonal disease characterized by heterogeneous involvement of hematopoietic bone marrow cell populations. In AML patients, a variety of clinical and biologic parameters, including surface markers, have been examinedfor potential value in predicting treatment response and survival. By checking the myeloid, lymphoid and nonspecific markers on the blasts, we tested the hypothesis which the disease free survival and overall survival in AML could correlate with the expression of them.
Methods: The immunophenotype was performed by multiparameter flow cytometry (FACS Caliber flow cytometry, Becton Dickinson). The prognostic significance of 16 antigens is taken separately in 207 adult AML patients. We applied statistical software of SPSS-13.  In this analysis, we compared DFS and OS with each of the surface markers existence.
Results: We could just find significant correlation in 4 of these markers. Those patients possessed CD3 blasts, had better overall survival (P=0.027). In contrast in CD33 patients, this parameter was worse (P=0.002). Disease free survival in CD15 patients was higher (P=0.036) but in CD34 cases, it was significantly lower (P=0.001).
Conclusions: This study suggests that dependent role of surface markers in the prognosis and response to treatment in AML is a fact which should be paid much more attention and applied it in the management of these patients.

Files
IssueVol 4, No 4 (2010) QRcode
SectionArticles
Keywords
Acute Myeloid Leukemia Disease Free Survival Overall Survival Surface Markers

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Sanaat Z, Amizadeh Y, Movasagpour Akbari A, Dolatkhah R. The Relationship between Immunological Markers, Disease Free Survival and Overall Survival in Acute Myeloid Leukemia in North-West of Iran. Int J Hematol Oncol Stem Cell Res. 1;4(4):25-28.